NANO-HYDROXYAPATITE IN BIOPOLYMERIC SCAFFOLDS FOR BONE

骨生物聚合物支架中的纳米羟基磷灰石

• 批准号: 6209591
• 负责人: DEBRA J TRANTOLO
• 金额: $ 15.19万
• 依托单位: CAMBRIDGE SCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-01 至 2003-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6209591
• 关键词: biodegradable product; biomaterial development /preparation; biomaterial evaluation; biomechanics; bone regeneration; crosslink; dicarboxylate; hydroxyapatites; nanotechnology; osteogenesis; polymers; tissue engineering; tissue support frame

DESCRIPTION: Many new polymer systems are being developed to accommodate biomaterial needs bone reconstruction. However, despite significant advances in the development of newer tissue engineering technologies to better approximate the complex three-dimensional nature of complex tissue equivalents, it has remained a challenge to develop clinically applicable bone replacement materials at least in part due to the difficulty to seed relatively thick scaffolds with cells (>1 mm) and to maintain cell viability for prolonged periods of time in vitro as well as in vivo. It is the purpose of this grant application to develop strong, bioactive biopolymeric bone graft materials using nanoparticulate hydroxyapatite ("nano-HA"). The overall objective is to employ nanoparticle technology to biopolymeric scaffolds to improve their ability to support cell penetration and maintain mechanical stability at bony repair sites. This Phase I project will investigate the feasibility of enhancing tissue responses in, as well as the mechanical integrity of, bony defects subject to repair or void filling using scaffold fashioned from a biopolymeric foam made via the crosslinking of poly(propylene glycol-co-fumaric) acid (PPF) in the presence of effervescent filters. PROPOSED COMMERCIAL APPLICATION: Bone is the second most implanted material in the body after blood. There are over 450,000 bone graft procedures annually in the U.S. (2.2 million worldwide) with a market potential of $400 to $600 million. New tissue engineered bone replacement materials would find a niche in this ever growing market.

描述：许多新的聚合物系统正在开发中以适应 生物材料需要骨骼重建。然而，尽管在 开发更新的组织工程技术以更好地近似 复杂组织等效物的复杂三维性质，它具有 开发临床适用的骨替代仍然是一个挑战 材料至少部分是由于难以播种相对厚的 具有细胞（> 1 mm）的支架并长期维持细胞活力 体外和体内的一段时间。这就是这笔赠款的目的 应用开发坚固的生物活性生物聚合骨移植材料 使用纳米颗粒羟基磷灰石（“nano-HA”）。总体目标是 将纳米颗粒技术应用于生物聚合物支架以改善其 支持细胞渗透并维持骨机械稳定性的能力 维修地点。该项目第一期将研究可行性 增强骨的组织反应以及机械完整性 使用由支架制成的缺陷需要修复或填充空隙 生物聚合泡沫由聚丙烯交联而成 乙二醇-富马酸) 酸 (PPF) 在泡腾过滤器存在下。 拟议的商业应用： 骨骼是体内第二大植入材料，仅次于血液。 有超过 美国每年进行 45 万例骨移植手术（全球 220 万例），有市场 潜力为 400 至 6 亿美元。 新型组织工程骨替代材料将 在这个不断增长的市场中找到一席之地。